Rostafuroxin
![]() | |
Names | |
---|---|
IUPAC name 21,23-Epoxy-24-nor-5β-chola-20,22-diene-3β,14β,17-triol | |
Systematic IUPAC name (1S,3aS,3bR,5aR,7S,9aS,9bS,11aS)-1-(Furan-3-yl)-9a,11a-dimethylhexadecahydro-3aH-cyclopenta[a]phenanthrene-1,3a,7-triol | |
Identifiers | |
CAS Number |
|
3D model (JSmol) |
|
PubChem CID |
|
UNII |
|
CompTox Dashboard (EPA) |
|
| |
Properties | |
Chemical formula | C23H34O4 |
Molar mass | 374.521 g·mol−1 |
Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa). Infobox references |
Chemical compound
Rostafuroxin is a digitoxigenin analog that has been shown to lower blood pressure in an animal model of hypertension.[1] It modulates the effects of the enzyme Na+/K+-ATPase,[1] which maintains sodium and potassium ion gradients across plasma membranes. Rostafuroxin is being studied in clinical trials for the treatment of essential hypertension.[2][3]
References
- ^ a b Ferrari, Patrizia; Ferrandi, Mara; Valentini, Giovanni; Bianchi, Giuseppe (2006). "Rostafuroxin: An ouabain antagonist that corrects renal and vascular Na+-K+- ATPase alterations in ouabain and adducin-dependent hypertension". American Journal of Physiology. Regulatory, Integrative and Comparative Physiology. 290 (3): R529–R535. doi:10.1152/ajpregu.00518.2005. PMID 16467500.
- ^ Ferrari, Patrizia (2010). "Rostafuroxin: An ouabain-inhibitor counteracting specific forms of hypertension". Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease. 1802 (12): 1254–1258. doi:10.1016/j.BBAdis.2010.01.009. PMID 20083196.
- ^ "Efficacy of Rostafuroxin in the Treatment of Essential Hypertension". clinicaltrials.gov.
- v
- t
- e